Interest of Propionibacterium Freudenreichii for the Treatment of Mild to Moderate Ulcerative Colitis

Inclusion Criteria: * Patient with age above 18 years old * Patient with diagnosis of ulcerative colitis for at least 6 months. * Patient with mayo endoscopic score ≥ 1 * Patient with mild to moderate disease activity (3 \< SCCI \< 12) * Ongoing treatment by mesalamine, steroids, thiopurines or Tumor Necrosis Factor antagonist at stable dose. * Patients who have given written informed consent. Exclusion Criteria: * Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty. * Psychiatric disease that alter the judgment * Stoma * Proctocolectomy * Severe disease (SCCI \>12, acute severe colitis) * Steroid dose \> 10 mg/j or introduction of steroid (topic or oral) within 4 weeks * Introduction or dose optimization of TNF antagonist within 4 months * Introduction or dose optimization of thiopurine * Hemoglobin level \< 11,5 g/dL, Platelets \> 400000/mm3, Leukocytosis \> 10 000/mm3 * Intolerant to lactose * Disease extent limited to the rectum * Mayo endoscopic subscore of 3